Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Pang, Li  [Clear All Filters]
Journal Article
Pang L, Liu Z, Wei F, Cai C, Yang X. Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools. Arch Toxicol. 2020.
Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HRong, Kraushaar U, Zeng H, et al. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Rep. 2018;24(13):3582-3592.
White MC, Pang L, Yang X. MicroRNA-mediated maturation of human pluripotent stem cell-derived cardiomyocytes: Towards a better model for cardiotoxicity?. Food Chem Toxicol. 2016.
Pang L, Cai C, Aggarwal P, Wang D, Vijay V, Bagam P, Blamer J, Matter A, Turner A, Ren L, et al. Predicting oncology Drug-Induced cardiotoxicity with Donor-Specific iPSC-CMs-a proof-of-Concept study with doxorubicin. Toxicol Sci. 2024.
Gintant G, Kaushik EPfeiffer, Feaster T, Stoelzle-Feix S, Kanda Y, Osada T, Smith G, Czysz K, Kettenhofen R, Lu HRong, et al. Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations. Regul Toxicol Pharmacol. 2020:104756.
Huo J, Wei F, Cai C, Lyn-Cook B, Pang L. Sex-related Differences in Drug-induced QT Prolongation and Torsades de Pointes: a New Model System with Human iPSC-CMs. Toxicol Sci. 2018.
Yang X, Ribeiro AJS, Pang L, Strauss DG. Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment. Toxicol Sci. 2022.
Pang L, Sager P, Yang X, Shi H, Sannajust F, Brock M, Wu JC, Abi-Gerges N, Lyn-Cook B, Berridge BR, et al. Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms. Circ Res. 2019;125(9):855-867.